US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
EP0381759A4
(en)
|
1988-07-25 |
1990-12-12 |
Vsesojuzny Kurgansky Nauchny Tsentr "Vosstanovitelnaya Travmatologia I Ortopedia" |
Traction apparatus for restoring the shape of the hand
|
TW219933B
(es)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
ES2101421T3
(es)
|
1993-11-02 |
1997-07-01 |
Hoechst Ag |
Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
|
ATE149485T1
(de)
|
1993-11-02 |
1997-03-15 |
Hoechst Ag |
Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
|
TW406076B
(en)
|
1993-12-30 |
2000-09-21 |
Hoechst Ag |
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
AU5762896A
(en)
|
1996-04-30 |
1997-11-19 |
Hoechst Aktiengesellschaft |
3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
CN1282319A
(zh)
|
1997-10-09 |
2001-01-31 |
小野药品工业株式会社 |
氨基丁酸衍生物
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
HUP0101482A3
(en)
|
1998-03-23 |
2002-12-28 |
Aventis Pharm Prod Inc |
Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
|
IL141423A
(en)
|
1998-08-27 |
2005-09-25 |
Teva Pharma |
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
JP2002531427A
(ja)
|
1998-11-27 |
2002-09-24 |
テバ ファーマシューティカル インダストリーズ リミティド |
セルトラリン塩酸塩多形体
|
US6500987B1
(en)
|
1998-11-27 |
2002-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride polymorphs
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
JP2003527319A
(ja)
|
1999-08-11 |
2003-09-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
トルセミド多形体
|
ES2349364T3
(es)
|
1999-11-17 |
2010-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica.
|
SK8312002A3
(en)
|
1999-12-14 |
2003-05-02 |
Biogal Gyogyszergyar |
Novel forms of pravastatin sodium
|
CA2397601A1
(en)
|
1999-12-16 |
2001-06-21 |
Teva Pharmaceutical Industries, Ltd. |
Novel processes for making- and a new crystalline form of- leflunomide
|
EP1254146B1
(en)
|
1999-12-16 |
2005-08-24 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing clarithromycin polymorphs and novel polymorph iv
|
IL150332A0
(en)
|
1999-12-21 |
2002-12-01 |
Teva Pharma |
Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
|
NZ519984A
(en)
|
2000-01-07 |
2004-03-26 |
Transform Pharmaceuticals Inc |
High-throughput formation, identification, and analysis of diverse solid-forms
|
PT1280535E
(pt)
|
2000-01-11 |
2005-04-29 |
Teva Pharma |
Processos para a preparacao de polimorfos de claritromicina
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
SK2242003A3
(en)
|
2000-07-27 |
2003-10-07 |
Teva Pharma |
Crystalline and pure modafinil, and process of preparing the same
|
CA2426158A1
(en)
|
2000-10-19 |
2002-06-13 |
Teva Pharmaceutical Industries Ltd. |
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
|
US20020183553A1
(en)
|
2000-10-19 |
2002-12-05 |
Ben-Zion Dolitzky |
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
|
PL366150A1
(en)
|
2000-10-30 |
2005-01-24 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
|
EP1332130A4
(en)
|
2000-11-03 |
2004-01-21 |
Teva Pharma |
HEMICALCIC ATORVASTATIN FORM VII
|
US7501450B2
(en)
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
IL156055A0
(en)
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
WO2002064557A2
(en)
|
2001-02-12 |
2002-08-22 |
Teva Pharmaceutical Industries Ltd. |
New crystal forms of oxcarbazepine and processes for their preparation
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
AU2002241154A1
(en)
|
2001-03-21 |
2002-10-03 |
Isis Innovation Ltd. |
Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
|
US20020177608A1
(en)
|
2001-04-09 |
2002-11-28 |
Ben-Zion Dolitzky |
Polymorphs of fexofenadine hydrochloride
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
JP2005523874A
(ja)
|
2001-08-01 |
2005-08-11 |
テバ ジョジセルジャール レースベニュタールシャシャーグ |
N−〔3−(3−シアノピラゾロ〔1,5−a〕ピリミジン−7−イル)フェニル〕−N−エチルアセタミド(ザレプロン)の精製方法、及び当該方法により得られうるザレプロンの結晶型
|
EP1436295A4
(en)
|
2001-09-07 |
2007-07-11 |
Teva Pharma |
CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
|
WO2003028665A2
(en)
|
2001-10-03 |
2003-04-10 |
Teva Pharmaceutical Industries Ltd. |
Methods for the purification of levofloxacin
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
CA2465913A1
(en)
|
2001-11-08 |
2003-05-15 |
Judith Aronhime |
Polymorphs of fexofenadine base
|
ES2234451T1
(es)
|
2001-11-14 |
2005-07-01 |
Teva Pharmaceutical Industries Ltd. |
Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
|
US6734314B2
(en)
|
2001-12-04 |
2004-05-11 |
Biogal Gyogyszergyar Rt. |
Preparation of orlistat and orlistat crystalline forms
|
CN100522946C
(zh)
|
2001-12-06 |
2009-08-05 |
法布罗根股份有限公司 |
低氧诱导因子(HIF)α的稳定化
|
PL370802A1
(en)
|
2001-12-18 |
2005-05-30 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of clopidogrel hydrogensulfate
|
EP1455769A4
(en)
|
2001-12-28 |
2004-09-22 |
Biogal Gyogyszergyar |
METHOD FOR PRODUCING CRYSTALLINE AND AMORPHIC MUPIROCIN CALCIUM
|
JP2005515226A
(ja)
|
2002-01-15 |
2005-05-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
カルベジロールの結晶質固体及びそれらを調製するための方法
|
EP1480950A4
(en)
|
2002-02-15 |
2005-05-18 |
Teva Pharma |
NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
|
US20030216376A1
(en)
|
2002-03-20 |
2003-11-20 |
Revital Lifshitz-Liron |
Crystalline forms of quetiapine hemifumarate
|
JP2005533755A
(ja)
|
2002-03-27 |
2005-11-10 |
テバ ファーマシューティカル インダストリーズ リミティド |
ランソプラゾール多形及びその調製方法
|
PL372964A1
(en)
|
2002-04-11 |
2005-08-08 |
Teva Pharmaceutical Indudstries, Ltd. |
Novel polymorphs and pseudopolymorphs of risedronate sodium
|
WO2003093217A1
(en)
|
2002-04-29 |
2003-11-13 |
Teva Pharmaceutical Industries Ltd. |
Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
|
CN1665803A
(zh)
|
2002-04-30 |
2005-09-07 |
特瓦药厂有限公司 |
新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法
|
JP2005534633A
(ja)
|
2002-05-10 |
2005-11-17 |
テバ ファーマシューティカル インダストリーズ リミティド |
ガチフロキサシンの新規結晶形
|
DE03757471T1
(de)
|
2002-06-10 |
2005-09-01 |
Teva Pharmaceutical Industries Ltd. |
Polymorphe form xvi von fexofenadin-hydrochlorid
|
US7411067B2
(en)
|
2002-06-14 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd |
Crystalline forms of gatifloxacin
|
AU2003253971A1
(en)
|
2002-07-18 |
2004-02-09 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
US7534913B2
(en)
|
2002-07-18 |
2009-05-19 |
Teva Pharmaceutica Industries Ltd. |
Crystalline form of nateglinide
|
US20040022764A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Hanan Polansky |
Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
|
EP1545530A1
(en)
|
2002-08-06 |
2005-06-29 |
Teva Pharmaceutical Industries Limited |
Novel crystalline forms of gatifloxacin
|
WO2004018470A2
(en)
|
2002-08-26 |
2004-03-04 |
Teva Pharmaceutical Industries Ltd. |
Crystalline solid famciclovir forms i, ii, iii and preparation thereof
|
US20050043329A1
(en)
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
EP1572643A2
(en)
|
2002-11-28 |
2005-09-14 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form f of atorvastatin hemi-calcium salt
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
EP1485097A1
(en)
|
2002-12-12 |
2004-12-15 |
Teva Pharmaceutical Industries Limited |
Crystalline forms of gatifloxacin and processes for preparation
|
AU2003300324A1
(en)
|
2002-12-24 |
2004-07-22 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
|
ES2245277T1
(es)
|
2003-03-12 |
2006-01-01 |
Teva Pharmaceutical Industries Limited |
Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
|
PL1507531T3
(pl)
|
2003-03-12 |
2007-06-29 |
Teva Pharma |
Trwałe kompozycje farmaceutyczne desloratadyny
|
ATE393764T1
(de)
|
2003-03-17 |
2008-05-15 |
Teva Pharma |
Polymorphe formen von valsartan
|
CN1802371A
(zh)
|
2003-05-15 |
2006-07-12 |
特瓦药厂有限公司 |
残余溶剂含量极低的阿兹托南β多晶型
|
EP2014660A3
(en)
|
2003-06-02 |
2009-07-15 |
Teva Pharmaceutical Industries Ltd |
Novel crystalline forms of valacyclovir hydrochloride
|
KR100880279B1
(ko)
|
2003-06-03 |
2009-01-28 |
테바 파마슈티컬 인더스트리즈 리미티드 |
결정성 지프라시돈 염산염 및 그의 제조 방법
|
CA2528232C
(en)
|
2003-06-06 |
2010-05-25 |
Fibrogen, Inc. |
Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
|
KR20070092993A
(ko)
|
2003-06-18 |
2007-09-14 |
테바 파마슈티컬 인더스트리즈 리미티드 |
플루바스타틴 나트륨 결정형 xiv, lxxiii,lxxix, lxxx 및 lxxxvii, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
|
US7368468B2
(en)
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
EP1567533B1
(en)
|
2003-07-03 |
2009-03-11 |
Teva Pharmaceutical Industries Ltd. |
Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
|
TW200526596A
(en)
|
2003-11-24 |
2005-08-16 |
Teva Pharma |
Crystalline ammonium salts of rosuvastatin
|
WO2005058819A2
(en)
|
2003-12-16 |
2005-06-30 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of tegaserod base and salts thereof
|
PT1613598E
(pt)
|
2003-12-16 |
2012-01-13 |
Teva Pharma |
Métodos para preparar formas cristalinas de aripiprazol
|
JP2007514001A
(ja)
|
2003-12-18 |
2007-05-31 |
テバ ファーマシューティカル インダストリーズ リミティド |
ジプラシドン塩基の多形形態b2
|
KR20060117356A
(ko)
|
2004-01-30 |
2006-11-16 |
테바 파마슈티컬 인더스트리즈 리미티드 |
몬테루카스트 유리산 다형체
|
WO2005075427A2
(en)
|
2004-01-30 |
2005-08-18 |
Teva Pharmaceutical Industries Ltd. |
Montelukast sodium polymorphs
|
US7692023B2
(en)
|
2004-02-11 |
2010-04-06 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
WO2005108370A1
(ja)
|
2004-04-16 |
2005-11-17 |
Ajinomoto Co., Inc. |
ベンゼン化合物
|
CA2560882A1
(en)
|
2004-04-26 |
2005-11-03 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of fexofenadine hydrochloride and processes for their preparation
|
EP1656339A1
(en)
|
2004-05-07 |
2006-05-17 |
Teva Pharmaceutical Industries Ltd |
Polymorphic forms of nateglinide
|
TW200613304A
(en)
|
2004-05-18 |
2006-05-01 |
Teva Pharma |
Drying process for preparing crystalline solid famciclovir
|
WO2005113481A1
(en)
|
2004-05-20 |
2005-12-01 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Preparation of levalbuterol hydrochloride
|
WO2006002348A2
(en)
|
2004-06-23 |
2006-01-05 |
Teva Pharmaceutical Industies Ltd. |
Solid and crystalline ibandronic acid
|
US20060142283A1
(en)
|
2004-06-29 |
2006-06-29 |
Judith Aronhime |
Crystalline form IV of linezolid
|
CA2576307A1
(en)
|
2004-07-01 |
2006-03-09 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of 1,24(s)-dihydroxy vitamin d2
|
CN101052631A
(zh)
|
2004-07-20 |
2007-10-10 |
特瓦药厂私人有限公司 |
结晶霉酚酸钠
|
CA2575243A1
(en)
|
2004-07-22 |
2006-02-02 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
|
CN1976894A
(zh)
|
2004-07-22 |
2007-06-06 |
特瓦药物精化学品股份有限公司 |
阿托莫西汀盐酸盐的多形体
|
JP4559431B2
(ja)
|
2004-08-23 |
2010-10-06 |
テバ ファーマシューティカル インダストリーズ リミティド |
固体及び結晶イバンドロネートナトリウム及びその調製方法
|
US20060154957A1
(en)
|
2004-09-21 |
2006-07-13 |
Nina Finkelstein |
Crystalline clopidogrel hydrobromide and processes for preparation thereof
|
JP2008514641A
(ja)
|
2004-09-28 |
2008-05-08 |
テバ ファーマシューティカル インダストリーズ リミティド |
結晶形フェキソフェナジン、およびその調製方法
|
WO2006050458A2
(en)
|
2004-11-02 |
2006-05-11 |
Teva Pharmaceutical Industries, Ltd. |
Tadalafil crystal forms and processes for preparing them
|
US20060293377A1
(en)
|
2004-11-03 |
2006-12-28 |
Shlomit Wizel |
Amorphous and polymorphic forms of telmisartan sodium
|
WO2006055964A2
(en)
|
2004-11-19 |
2006-05-26 |
Teva Pharmaceutical Industries Ltd. |
Zolmitriptan crystal forms
|
EP1817315A1
(en)
|
2004-12-01 |
2007-08-15 |
Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság |
Processes for producing crystalline macrolides
|
JP2007526251A
(ja)
|
2004-12-03 |
2007-09-13 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミベ多形体
|
MX2007007301A
(es)
|
2005-01-11 |
2008-02-11 |
Teva Pharm Fine Chemicals Srl |
Polimorfos de clorhidrato de memantina.
|
US20060270859A1
(en)
|
2005-01-27 |
2006-11-30 |
Santiago Ini |
Duloxetine HCl polymorphs
|
WO2006084210A2
(en)
|
2005-02-04 |
2006-08-10 |
Regents Of The University Of California, San Diego |
Hif modulating compounds and methods of use thereof
|
AU2006216695A1
(en)
|
2005-02-24 |
2006-08-31 |
Teva Pharmaceutical Industries, Ltd. |
Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
|
CA2602073A1
(en)
|
2005-02-24 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of linezolid intermediate
|
EP1856087A1
(en)
|
2005-03-08 |
2007-11-21 |
Teva Pharmaceutical Industries Limited |
Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
|
EP1858891A2
(en)
|
2005-03-14 |
2007-11-28 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ziprasidone mesylate
|
CN101160281A
(zh)
|
2005-04-06 |
2008-04-09 |
特瓦制药工业有限公司 |
结晶形态的普瑞巴林
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
WO2006127935A1
(en)
|
2005-05-23 |
2006-11-30 |
Cadbury Adams Usa Llc |
Taste potentiator compositions and beverages containing same
|
JP2008507565A
(ja)
|
2005-05-23 |
2008-03-13 |
テバ ファーマシューティカル インダストリーズ リミティド |
シナカルセトの精製
|
CN101849943A
(zh)
|
2005-06-06 |
2010-10-06 |
菲布罗根公司 |
使用HIFα稳定剂的改进的贫血治疗
|
US20070043099A1
(en)
|
2005-06-09 |
2007-02-22 |
Igor Lifshitz |
Crystalline forms of carvedilol and processes for their preparation
|
US20070100165A1
(en)
|
2005-06-09 |
2007-05-03 |
Ronen Borochovitz |
Process for preparation of sertraline hydrochloride form I
|
MX2007016160A
(es)
|
2005-06-15 |
2008-03-07 |
Fibrogen Inc |
Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
|
US20070112057A1
(en)
|
2005-06-22 |
2007-05-17 |
Santiago Ini |
Polymorphic forms of tegaserod maleate
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
WO2007038676A2
(en)
|
2005-09-28 |
2007-04-05 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of ladostigil tartrate
|
US20090176726A1
(en)
|
2005-10-11 |
2009-07-09 |
Fisher David E |
Methods for treating mitf-related disorders
|
SI1937642T1
(sl)
|
2005-10-19 |
2015-01-30 |
Teva Pharmaceutical Industries Ltd. |
Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
|
JP2008526782A
(ja)
|
2005-10-31 |
2008-07-24 |
テバ ファーマシューティカル インダストリーズ リミティド |
セフジニルセシウム塩結晶
|
JP2008525531A
(ja)
|
2005-10-31 |
2008-07-17 |
テバ ファーマシューティカル インダストリーズ リミティド |
セフジニルカリウム塩の結晶形
|
WO2007059307A2
(en)
|
2005-11-15 |
2007-05-24 |
Teva Pharmaceutical Industries Ltd. |
Crystalline and amorphous forms of telithromycin
|
WO2007062147A1
(en)
|
2005-11-22 |
2007-05-31 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms of cinacalcet hci and processes for their preparation
|
ES2446416T3
(es)
|
2005-12-09 |
2014-03-07 |
Amgen, Inc. |
Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
|
TW200745026A
(en)
|
2005-12-13 |
2007-12-16 |
Teva Pharma |
Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
|
EP1968978A2
(en)
|
2006-01-05 |
2008-09-17 |
Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság |
Forms of dolasetron mesylate and processes for their preparation
|
BRPI0706377A2
(pt)
|
2006-01-09 |
2011-03-22 |
Btg Int Ltd |
moduladores de fator -1 induzìvel por hipoxia e usos relacionados
|
EP1983823A1
(en)
|
2006-01-17 |
2008-10-29 |
VIB vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
US20070208072A1
(en)
|
2006-01-18 |
2007-09-06 |
Gustavo Frenkel |
Maleate salt of tegaserod and crystalline forms thereof
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
TW200738709A
(en)
|
2006-01-19 |
2007-10-16 |
Osi Pharm Inc |
Fused heterobicyclic kinase inhibitors
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
WO2007098273A2
(en)
|
2006-02-21 |
2007-08-30 |
Teva Pharmaceutical Industries Ltd. |
Novel crystalline forms of armodafinil and preparation thereof
|
MX2007013286A
(es)
|
2006-02-27 |
2008-03-07 |
Teva Pharma |
Formas novedosas de sodio de fluvastatina y preparacion de ellas.
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
TW200808793A
(en)
|
2006-03-07 |
2008-02-16 |
Smithkline Beecham Corp |
Prolyl hydroxylase inhibitors
|
WO2007109799A2
(en)
|
2006-03-23 |
2007-09-27 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
WO2007136990A2
(en)
|
2006-05-16 |
2007-11-29 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
TWI394747B
(zh)
|
2006-06-23 |
2013-05-01 |
Smithkline Beecham Corp |
脯胺醯基羥化酶抑制劑
|
DK3357911T3
(da)
|
2006-06-26 |
2022-07-04 |
Akebia Therapeutics Inc |
Prolylhydroxylaseinhibitorer og fremgangsmåder til anvendelse
|
CL2008000065A1
(es)
|
2007-01-12 |
2008-09-22 |
Smithkline Beecham Corp |
Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
|
TW200845991A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: hydroxylase inhibitors
|
US20100056563A1
(en)
|
2007-04-18 |
2010-03-04 |
Deodialsingh Guiadeen |
Novel 1.8-naphthyridine compounds
|
ES2446418T3
(es)
|
2007-04-18 |
2014-03-07 |
Amgen, Inc |
Derivados de indanona que inhiben la prolil hidroxilasa
|
WO2008137060A1
(en)
|
2007-05-04 |
2008-11-13 |
Amgen Inc. |
Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
|
CA2685942A1
(en)
|
2007-05-16 |
2008-11-27 |
Merck & Co., Inc. |
Spiroindalones
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
EP2188295A4
(en)
|
2007-08-10 |
2011-11-16 |
Crystalgenomics Inc |
PYRIDINE DERIVATIVES AND METHODS OF USE
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009061910A1
(en)
|
2007-11-08 |
2009-05-14 |
Genetech, Inc. |
Anti-factor b antibodies and their uses
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
US20100305154A1
(en)
|
2007-11-30 |
2010-12-02 |
Glaxosmithkline Llc |
Prolyl Hydroxylase Inhibitors
|
EP2227770A4
(en)
|
2007-11-30 |
2011-11-09 |
Glaxosmithkline Llc |
PROLYLHYDROXYLASEINHIBITOREN
|
US8269008B2
(en)
|
2007-12-03 |
2012-09-18 |
Fibrogen, Inc. |
Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
|
WO2009086044A1
(en)
|
2007-12-19 |
2009-07-09 |
Smith Kline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009086592A1
(en)
|
2008-01-04 |
2009-07-16 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
US8952160B2
(en)
|
2008-01-11 |
2015-02-10 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
US20120329836A1
(en)
|
2011-06-06 |
2012-12-27 |
The Ohio State University |
Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
|
NO2686520T3
(es)
|
2011-06-06 |
2018-03-17 |
|
|
KR102029951B1
(ko)
|
2011-07-22 |
2019-11-08 |
베이징 베타 파머수티컬 컴퍼니 리미티드 |
프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
|
US8772895B2
(en)
|
2011-11-28 |
2014-07-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Dark current reduction for back side illuminated image sensor
|
EP2637274B1
(en)
|
2012-03-05 |
2022-05-04 |
Vetco Gray Scandinavia AS |
Power cable termination arrangement
|
US11857543B2
(en)
|
2013-06-13 |
2024-01-02 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating anemia
|
CR20200220A
(es)
|
2013-11-15 |
2020-11-18 |
Akebia Therapeutics Inc |
FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
|
MX2016009331A
(es)
|
2014-01-23 |
2016-10-26 |
Akebia Therapeutics Inc |
Composiciones y metodos para tratar enfermedades oculares.
|
JP2018502882A
(ja)
|
2015-01-23 |
2018-02-01 |
アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. |
2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用
|
US20180065933A1
(en)
|
2015-03-20 |
2018-03-08 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
MX2017012460A
(es)
|
2015-04-01 |
2018-01-30 |
Akebia Therapeutics Inc |
Composiciones y metodos para el tratamiento de la anemia.
|
JP2020500925A
(ja)
|
2016-12-13 |
2020-01-16 |
クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド |
{[5−(3−クロロフェニル)−3−ヒドロキシピリジン−2−カルボニル]アミノ}酢酸の新規結晶形及びその製造方法
|
TWI822776B
(zh)
|
2018-05-09 |
2023-11-21 |
美商阿克比治療有限公司 |
用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
|
KR20220133176A
(ko)
|
2019-10-31 |
2022-10-04 |
아케비아 테라퓨틱스 인코포레이티드 |
바다두스타트를 사용하는 치료 방법
|
US11524939B2
(en)
|
2019-11-13 |
2022-12-13 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
|